Prosecution Insights
Last updated: April 19, 2026

Vertex Pharmaceuticals Incorporated

17 pending office actions

Portfolio Summary

17
Total Pending OAs
8
Final Rejections
9
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18647137 STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION DICKINSON, PAUL W 1618 Non-Final OA Apr 26, 2024
18566176 SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE RAO, PADMAJA S 1627 Non-Final OA Dec 01, 2023
18248068 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FETTEROLF, BRANDON J 1626 Final Rejection Apr 06, 2023
18030529 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FETTEROLF, BRANDON J 1626 Final Rejection Apr 06, 2023
18030527 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FETTEROLF, BRANDON J 1626 Final Rejection Apr 06, 2023
18030518 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VISHNYAKOVA, ELENA VLADIMIROVNA 1691 Non-Final OA Apr 06, 2023
18030530 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FETTEROLF, BRANDON J 1626 Final Rejection Apr 06, 2023
18248071 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FETTEROLF, BRANDON J 1626 Final Rejection Apr 06, 2023
18030537 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FETTEROLF, BRANDON J 1626 Final Rejection Apr 06, 2023
18018787 IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS ROGERS, ERIC JASON 1638 Non-Final OA Jan 30, 2023
17916484 INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) O DELL, DAVID K 1621 Non-Final OA Sep 30, 2022
17820773 METHOD FOR TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS HOWELL, THEODORE R 1628 Non-Final OA Aug 18, 2022
17669874 PANCREATIC DIFFERENTIATION BATES, KEENAN ALEXANDER 1631 Final Rejection Feb 11, 2022
17560680 ENHANCED DIFFERENTIATION OF BETA CELLS NGUYEN, NGHI V 1653 Non-Final OA Dec 23, 2021
17345256 INHIBITORS OF APOL1 AND METHODS OF USING SAME CHICKS, ASHLI ARIANA 1626 Non-Final OA Jun 11, 2021
17293632 METHODS OF TREATMENT FOR CYSTIC FIBROSIS LEE, HOI YAN NMN 1693 Non-Final OA May 13, 2021
16845280 GENE-EDITING SYSTEMS FOR MODIFYING A SCN9A OR SCN10A GENE AND METHODS OF USE THEREOF SHIN, DANA H 1635 Final Rejection Apr 10, 2020

Managing Vertex Pharmaceuticals Incorporated's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month